Merck & Co alters safety monitoring and pays lawyer fees to end US Vioxx suits
This article was originally published in Scrip
Executive Summary
Merck & Co has agreed to pay up $12.5 million in plaintiffs' legal fees to settle shareholder "derivative" suits in US state and federal courts that allege breach of financial duties by senior executives over the withdrawn painkiller Vioxx (rofecoxib).